Abstract:BackgroundAlpha fetoprotein (AFP) is a circulating tumor marker utilized clinically to detect liver cirrhosis, liver cancer and testicular seminomas. AFP molecule contains one single N-glycosylation site, with highly variable glycan structures, resulting in diverse AFP glycoforms in circulating blood. The core fucosylation of AFP (AFP-L3) is a clinical biomarker to monitor and predict risks of liver cancer progression and recurrence. Clinical testing for AFP-L3 utilizes lectin-binding and gel-shift electrophoresis. We developed a novel method to measure AFP glycoforms, based on immune-enrichment and liquid chromatography with high resolution mass spectrometry (LC-HRMS).MethodsImmune enrichment of AFP was achieved by anti-AFP antibody, immobilized to magnetic beads. After binding and enrichment, the magnetic beads were washed, AFP was eluted, and the samples were analyzed by LC-HRMS (Exploris 480 MS and Vanquish UHPLC, Thermo Fisher Scientific), using full scan, positive polarity acquisition mode. Chromatographic separation was performed on PLRP column (Agilent); flow rate 200 μL/min. The HRMS data were processed and deconvoluted with intact mass analysis workflow in Biopharma Finder 5.1 (Thermo Fisher Scientific) to derive the intact AFP masses. The method's sensitivity and imprecision were assessed by replicate analysis of serial diluted patient serum samples. AFP and its associated glycoforms were matched and identified with an in-house developed bioinformatics workflow. The deconvoluted intact masses and the sum intensity of detected charged species for each AFP glycoform were used to quantify relative abundance of AFP glycoforms.ResultsThe method specificity for AFP was confirmed by bottom-up analysis after immune-enrichment with observed peptide sequence coverage over 35%. The recovery of the immune enrichment was shown to be independent of the AFP glycoform compositions. The identified AFP glycoforms and their relative abundance were consistent among replicates between AFP concentration 100 ng/mL and 5000 ng/mL. Analysis of authentic serum specimens from patients with different chronic liver diseases and liver cancer (n=102), revealed multiple complex biantennary branched AFP glycan modifications, with different numbers of terminal sialic acid and core fucose. Four AFP glycoforms were identified in over 60% patient samples with elevated AFP concentrations. Although occurring consistently, relative abundance of these AFP glycoforms varied significantly among patients. Assessment of the AFP fucosylation and sialylation features suggested that the two are orthogonal processes. Clinical correlations suggested that fewer terminal sialic acids were associated with impaired liver functions, while the fucosylation was linked to inflammatory responses and presence of liver malignancy. Strong linear correlation (Spearman's rs=0.952, N=35) was observed between AFP-L3% quantitated by the LC-HRMS method, and AFP-L3% determined by the lectin-binding based isotachophoresis assay (Wako Diagnostics). Discrepancies between the two methods were observed in specimens containing < 400 ng/mL of AFP, in which the LC-HRMS method detected only a single predominant glycoform.ConclusionsWe developed and evaluated the LC-HRMS method for profiling circulating AFP glycoforms in patients with chronic liver diseases and liver cancer. The detected AFP glycoforms and their relative abundance were used to establish glycan features, which can be further linked to cancer development, impaired liver function, and inflammation.

Identification of N-glycan of Alpha-Fetoprotein by Lectin Affinity Microarray

Identification of N-glycan moiety of tumor marker by lectin microarray

Glycosylation Profiling of the Neoplastic Biomarker Alpha Fetoprotein through Intact Mass Protein Analysis

Multiplex profiling of glycoproteins using a novel bead-based lectin array.

B-149 Diverse glycosylation of circulating alpha fetoprotein in chronic liver diseases profiled by intact mass high resolution mass spectrometry

Detection and Discrimination of Alpha-Fetoprotein with a Label-Free Electrochemical Impedance Spectroscopy Biosensor Array Based on Lectin Functionalized Carbon Nanotubes

Glycoprofiling of Early Non-Small Cell Lung Cancer Using Lectin Microarray Technology

Multiple Lectin Assays for Detecting Glyco-Alteration of Serum GP73 in Liver Diseases

Membrane Protein Glycanprofiling of Hepatocellular Carcinoma Cell with Different Metastastic Potential by Lectin Microarray*

N-glycan fingerprint predicts alpha-fetoprotein negative hepatocellular carcinoma: A large-scale multicenter study

Sensing Lectin–glycan Interactions Using Lectin Super-Microarrays and Glycans Labeled with Dye-Doped Silica Nanoparticles

The use of lectin microarray for assessing glycosylation of therapeutic proteins

Analysis of Alpha-Fetoprotein Variants by Using a Modified Lectin-Affinity Immunoelectrophoresis Autoradiography

Application Of Lectin Affinity Methods In Analysis And Detection Of Glycoprotein Cancer Biomarkers

Application of Lectin Microarrays for Biomarker Discovery

Heterogeneities of Site-Specific N-Glycosylation in HCC Tumors with Low and High AFP Concentrations

A Simple, Rapid and Sensitive Sandwich Immunoassay Based on Poly(n-Isopropylacrylamide) for the Detection of Alpha-Fetoprotein

Antibody modified gold nano-mushroom arrays for rapid detection of alpha-fetoprotein

Molecularly Imprinted Polymers Outperform Lectin Counterparts and Enable More Precise Cancer Diagnosis.

Sandwich Immunoassay for Alpha-Fetoprotein in Human Sera Using Gold Nanoparticle and Magnetic Bead Labels along with Resonance Rayleigh Scattering Readout

Identification of serum glycobiomarkers for Hepatocellular Carcinoma using lectin microarrays